Treatment of venous thromboembolism (VTE) presenting clinically as deep vein thrombosis (DVT), pulmonary embolism (PE) or both.
For this indication, competent medicine agencies globally authorize below treatments:
Subcutaneous
200 - 200 [iU] per kg of body weight
From 100 To 100 [iU] per kg of body weight 2 time(s) per day every day
A dose of 100 IU/kg body weight administered s.c twice daily can be used for patients with increased risk of bleeding. Monitoring of the treatment is generally not necessary but can be performed with a functional anti-Factor Xa assay. Maximum plasma levels are obtained 3-4 hours after s.c injection, when samples should be taken. Recommended plasma levels are between 0.5-1.0 IU (anti-Factor Xa)/ml.
Simultaneous anticoagulation with oral vitamin K antagonists can be started immediately. Treatment with Fragmin is continued until the prothrombin complex levels (factor II, VII, IX and X) have decreased to a therapeutic level. At least five days of combined treatment is normally required.
Subcutaneous
200 - 200 [iU] per kg of body weight
From 200 To 200 [iU] per kg of body weight once every day
200 IU/kg body weight is administered s.c once daily. Monitoring of the anticoagulant effect is not necessary. The single daily dose should not exceed 18,000 IU.
Simultaneous anticoagulation with oral vitamin K antagonists can be started immediately. Treatment with dalteparin is continued until the prothrombin complex levels (factor II, VII, IX and X) have decreased to a therapeutic level. At least five days of combined treatment is normally required.